物理性质
- 熔点-57 °C
- 沸点114-116°C
- 闪点1.629
- 密度1.629 g/mL at 25 °C(文献)
- PSA:17.07
- LogP:2.122
- 折射率1.469 - 1.471
- 蒸汽压21.32 mm Hg @ 25 °C, determined from experimentally derived coefficients
- 溶解性可溶于氯仿,乙酸乙酯
- 敏感性TRICHLOROACETYL CHLORIDE is incompatible with water, with strong oxidizing agents, alcohols, bases (including amines). May react vigorously or explosively if mixed with diisopropyl ether or other ethers in the presence of trace amounts of metal salts [J. Haz. Mat., 1981, 4, 291].
- 外观形态无色油状物
- 储存条件本品应密封存放于阴凉,干燥处.
- 产品应用用作军用毒气,也用于有机合成.
- 性质描述无色有刺激性气味液体.熔点-57°C,沸点114-116°C,相对密度1.541-1.543(20).遇水,醇分解,并放出大量的氯化氢
MSDS等安全信息
- GHS象形图


- GHS符号GHS06 & GHS05;
注释: Skull and crossbones & Corrosion - 危险类别急性毒性 类别1(吸入)
急性毒性 类别4(经口)
皮肤腐蚀 类别1B
金属腐蚀物 类别1
急性毒性 类别2(吸入)
皮肤腐蚀 类别1A
严重眼损伤 类别1
特定目标器官毒性 - 单次接触 类别3
皮肤腐蚀/刺激 类别2
严重眼刺激 类别2
皮肤腐蚀 类别1
皮肤致敏 类别1
水生急性毒性 类别1
水生慢性毒性 类别1 - 警示词Danger(危险)
- 危险描述H330 |吸入致命.
H302 |吞咽有害.
H314 |造成严重皮肤灼伤和眼损伤.
H290 |可能对金属造成腐蚀.
H318 |造成严重眼损伤.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
H317 |可能引起皮肤过敏反应.
H400 |对水生生物毒性极大.
H410 |对水生生物毒性极大并具有长期持续影响. - 防范说明P260,P280,P284,P305+P351+P338,P310
- UN编号2442.0
- 危险品标志T+
- 安全声明S23,S26,S28,S28A,S36/37/39,S45,S8
- 危险类别码R14,R22,R26,R35,R29
- WGK Germany3
欧盟法规
REACH注册ECHA物质ECHA物质C&L通报REACH预注册上下游产品
二氯乙酰氯 Dichloroacetyl Chloride 79-36-7四氯乙烯置于2,2,3,3,3-五氟丙基甲醚,氯体系中,24.84 °C,1.01 Mpa 条件下,反应生成 三氯乙酰氯
参考文献:Reactions Of Chloroethenes With Atomic Chlorine In Air At Atmospheric Pressure
标题:Reactions Of Chloroethenes With Atomic Chlorine In Air At Atmospheric Pressure
摘要:在298 K和1013 Hpa条件下,采用相对速率法和gc-Ms检测技术研究了cl原子与h2C=ccl2,Cis-Clhc=chcl,Trans-Clhc=chcl,Clhc=ccl2和cl2C=ccl2反应的动力学.反应产物通过ftir光谱得以鉴定.同时,提出了氯乙烯在大气中的降解机理.
DOI:10.1007/s11172-010-0158-4
海关参考信息
- 2903130000-三氯甲烷
2903150000-1,2-二氯乙烷
2912110000-甲醛
2912120000-乙醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-6683189-B1
优先权日:1996-02-26
标 题 :Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
发明人:DERVAN PETER B; BAIRD ELDON
权利人:CALIFORNIA INST OF TECHN
摘要:The present invention describes a novel method for the solid phase synthesis of polyamides containing imidazole and pyrrole carboxamides. The polyamides are prepared on a solid support from aromatic carboxylic acids and aromatic amines with high stepwise coupling yields (>99%), providing milligram quantities of highly pure polyamides. The present invention also describes the synthesis of analogs of the natural products Netropsin and Distamycin A, two antiviral antibiotics. The present invention also describes a novel method for the solid phase synthesis of imidazole and pyrrole carboxamide polyamide-oligonucleotide conjugates. This methodology will greatly increase both the complexity and quantity of minor-groove binding polyamides and minor-groove binding polyamide-oligonucleotide conjugates which can be synthesized and tested.
专利号:US-8138330-B2
优先权日:2006-09-11
标 题 :Process for the synthesis of oligonucleotides
发明人:LEUCK MICHAEL; WOLTER ANDREAS; STUMPE ALFRED
权利人:LEUCK MICHAEL; WOLTER ANDREAS; STUMPE ALFRED; SIGMA ALDRICH CO LLC
摘要:The present invention discloses novel methods for the synthesis of oligonucleotides with nucleoside phosphoramidites on solid supports. The methods comprise the stepwise chain assembly of oligonucleotides on supports with 5′-acyl phosphoramidites. The synthesis cycles consist of a front end deprotection step which is conducted with a solution of a primary amine or a phenolate, a phosphoramidite coupling step with a 5′-acyl nucleoside phosphoramidite in the presence of an activator, a phosphite oxidation step and an optional capping step. The novel methods improve the quality of synthetic oligonucleotides due to the irreversibility of the front end deprotection step, which prevents the formation of deletion sequences, and due to the avoidance of acidic reagents in the synthesis cycles, which prevent the formation of depurination side products. The invention further discloses novel nucleoside phosphoramidite compositions wherein the phosphoramidites carry acyl front end protective groups which are cleavable with primary amines or phenolates. The invention is applicable to the synthesis of oligodeoxyribonucleotides, oligoribonucleotides and oligonucleotides with modifications in their sugar or phosphate groups.
专利号:US-2024024489-A1
优先权日:2020-11-20
标 题:Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof
发明人:MULARD LAURENCE; DHARA DEBASHIS; PFISTER HELENE; PAOLETTI JULIE; PHALIPON ARMELLE; GUERREIRO-INVERNO CATHERINE
权利人:PASTEUR INSTITUT
摘要:The present invention provides zwitterionic oligosaccharides, in particular fragments of the surface polysaccharides from Shigella sonnei and Shigella sonnei conjugates comprising them. The present invention also provides protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof, the disaccharide repeating unit of Shigella sonnei being: (I)
专利号:US-4756739-A
优先权日:1985-12-21
标题 :Pyridine derivatives and the N-oxides thereof, and the use thereof as intermediates for the synthesis of plant protecting agents
发明人:FUSS ANDREAS; KOCH VOLKER
权利人:HOECHST AG
摘要:The compounds of the formula I (I) in which A denotes N or N->O, Z denotes O or NH, R denotes H, (halo)alkyl, (halo)alkenyl, (halo)alkynyl or alkoxycarbonyl, R1 denotes hydrogen, halogen, amino, -NHOH, hydroxyl, (substituted) phenylazo or a radical of the formulae Y=C=N-, Y1Y2C=N-, Y3NH- or K denotes 0 or 1, and m and n, independently of one another, denote a number from 1 to 4, with the proviso that, when Z-R denotes OH or NH2, (R1)n denotes at least one radical of the formula or represents two radicals, in the 5 or 6 position of the heterocyclic ring, which, in the 5 position, denote halogen and, in the 6 position, denote a radical of the group comprising halogen, amino, hydroxyl or phenylazo, which may be substituted as specified above, are valuable intermediates in the synthesis of plant protection agents.
专利号:US-7098354-B2
优先权日:2002-10-25
标 题:Racemoselective synthesis of rac-diorganosilylbis(2-methylbenzo[e]indeyl)zirconium compounds
发明人:DAMRAU HANS-ROBERT; MUELLER PATRIK; GARCIA VALERIE; SIDOT CHRISTIAN; TELLIER CHRISTIAN; LELONG JEAN-FRANCOIS
权利人:BASELL POLYOLEFINE GMBH
摘要:The present invention relates to a specific process for the diastereoselective synthesis of rac-diorganosilylbis(2-methylbenzo[e]indenyl)zirconium compounds of the formula I, n nby reacting the silyl-bridged bisindenyl ligand with a dihalozirconium bis(3,5-di-tert-butylphenoxide)-base adduct to form the diorganosilylbis(2-methylbenzo[e]indenyl)zirconium bis(3,5-di-tert-butylphenoxide) and subsequently replacing the phenoxide groups by X using suitable replacement reagents to give the compound of the formula I; where the substituents X can be identical or different and are each F, Cl, Br, I or linear, cyclic or branched C 1-10 -alkyl; and the substituents R can be identical or different and are each linear, cyclic or branched C 1-10 -alkyl or C 6-10 -aryl; and also to the use of these compounds as catalysts.
专利号:US-6172205-B1
优先权日:1997-12-11
标题 :Synthetic process toward total synthesis of eleutherobin and its analogues and uses thereof
发明人:DANISHEFSKY SAMUEL J; CHEN XIAO-TAO; GUTTERIDGE CLARE E; BHATTACHARYA SAMIT K; ZHOU BISHAN
权利人:TRUSTEES OF COLUMBIA IN THE CI
摘要:This invention provides a process for the preparation of a Eleutherobin derivative of the formula: n wherein R 1 is a hydrogen, ester, nitrile or C 2 H 4 —R wherein R 4 is a carbohydrate, an alcohol an amine, an amide, an alkyne, or, R 2 is a linear or branched alkyl moiety, R 3 is an ester, an amide, a carbamate, an acetal compound,an ether or a urethane, R 4 is a hydrogen or CH 2 ,position C 2 and C 3 is cis or trans,position C 8 is α or β and a compound is produced having the structures: n Additionally, this experiment provides a method for inhibiting growth of cancerous cells comprising contracting an amount of Eleutherobin derivative effective to inhibit the growth of said cells. Further provided is a method for treating cancer in a subject which comprises administering to the subject a therapeutically effective amount of the Eleutherobin derivative.